EVELO BIOSCIENCES INC: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei EVELO BIOSCIENCES INC listata cu simbolul US.EVLO ==Descriere companie== Evelo Biosciences, Inc. (https://evelobio.com/) is a biotechnology company. The Company is focused on discovering and developing a class of orally delivered medicines that act on cells in the small intestine with systemic therapeutic effects. Its product candidates are pharmaceutical preparations of single strains of microbes or microbial extracellular vesicles selected for the...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Evelo Biosciences, Inc. (https://evelobio.com/) is a biotechnology company. The Company is focused on discovering and developing a class of orally delivered medicines that act on cells in the small intestine with systemic therapeutic effects. Its product candidates are pharmaceutical preparations of single strains of microbes or microbial extracellular vesicles selected for their ability to modulate the immune system through SINTAX, the small intestinal axis. It has several product candidates in development with the potential to treat a range of inflammatory diseases, including COVID-19, and cancer. Its product candidates include EDP1815, EDP1867 and EDP2939 for the treatment of inflammatory diseases, and EDP1908 for the treatment of cancer. | [[Evelo Biosciences]], Inc. (https://evelobio.com/) is a biotechnology company. The Company is focused on discovering and developing a class of orally delivered medicines that act on cells in the small intestine with systemic therapeutic effects. Its product candidates are pharmaceutical preparations of single strains of microbes or microbial extracellular vesicles selected for their ability to modulate the immune system through SINTAX, the small intestinal axis. It has several product candidates in development with the potential to treat a range of inflammatory diseases, including COVID-19, and cancer. Its product candidates include EDP1815, EDP1867 and EDP2939 for the treatment of inflammatory diseases, and EDP1908 for the treatment of cancer. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||
Versiunea curentă din 30 septembrie 2024 18:55
Pagina dedicata companiei EVELO BIOSCIENCES INC listata cu simbolul US.EVLO
Descriere companie[edit | ]
Evelo Biosciences, Inc. (https://evelobio.com/) is a biotechnology company. The Company is focused on discovering and developing a class of orally delivered medicines that act on cells in the small intestine with systemic therapeutic effects. Its product candidates are pharmaceutical preparations of single strains of microbes or microbial extracellular vesicles selected for their ability to modulate the immune system through SINTAX, the small intestinal axis. It has several product candidates in development with the potential to treat a range of inflammatory diseases, including COVID-19, and cancer. Its product candidates include EDP1815, EDP1867 and EDP2939 for the treatment of inflammatory diseases, and EDP1908 for the treatment of cancer.
Grafic actiuni companie[edit | ]